NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.33 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,406,306 | -58.7% | 18,136,735 | 0.0% | 12.88% | -29.3% |
| Q2 2023 | $46,974,144 | -36.5% | 18,136,735 | 0.0% | 18.23% | -31.9% |
| Q1 2023 | $73,997,879 | -18.7% | 18,136,735 | 0.0% | 26.76% | -11.7% |
| Q4 2022 | $91,046,410 | -61.6% | 18,136,735 | 0.0% | 30.31% | -42.3% |
| Q3 2022 | $237,228,000 | +2.0% | 18,136,735 | 0.0% | 52.50% | +6.1% |
| Q2 2022 | $232,513,000 | -6.1% | 18,136,735 | +11.6% | 49.48% | +7.7% |
| Q1 2022 | $247,749,000 | -9.1% | 16,245,817 | +5.5% | 45.93% | +23.9% |
| Q4 2021 | $272,665,000 | -15.7% | 15,396,116 | 0.0% | 37.08% | +0.7% |
| Q3 2021 | $323,626,000 | +6.6% | 15,396,116 | 0.0% | 36.81% | -14.3% |
| Q2 2021 | $303,611,000 | -32.2% | 15,396,116 | 0.0% | 42.97% | +0.2% |
| Q1 2021 | $447,565,000 | -4.1% | 15,396,116 | 0.0% | 42.88% | +1.3% |
| Q4 2020 | $466,502,000 | – | 15,396,116 | – | 42.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |